Protara Therapeutics Inc (TARA)
2.92
-0.06
(-2.01%)
USD |
NASDAQ |
May 01, 16:00
2.92
0.00 (0.00%)
After-Hours: 20:00
Protara Therapeutics Cash from Operations (TTM): -37.56M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -37.56M |
September 30, 2023 | -33.88M |
June 30, 2023 | -32.67M |
March 31, 2023 | -28.38M |
December 31, 2022 | -26.46M |
September 30, 2022 | -28.34M |
June 30, 2022 | -29.19M |
Date | Value |
---|---|
March 31, 2022 | -33.54M |
December 31, 2021 | -34.50M |
September 30, 2021 | -34.36M |
June 30, 2021 | -31.92M |
March 31, 2021 | -28.18M |
December 31, 2020 | -23.41M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-37.56M
Minimum
Dec 2023
-23.41M
Maximum
Dec 2020
-30.95M
Average
-31.92M
Median
Jun 2021
Cash from Operations (TTM) Benchmarks
AngioDynamics Inc | -17.20M |
Regulus Therapeutics Inc | -26.77M |
Bio-Path Holdings Inc | -11.54M |
Outset Medical Inc | -131.37M |
AN2 Therapeutics Inc | -53.29M |